CRAMS growth helps Jubilant in fiscal 2010
International demand for contract manufacturing helped India’s Jubilant Organosys finish fiscal 2010 with a quarter of growth.
Archives for May 10, 2010
DSM: XD scale-up can cut drug production costs
DSM Biologics says successful XD tech expansion paves way for smaller bioreactors that lowers cost of production facilities and, ultimately, of bio-drug manufacture.